In Vitro: GLPG0259 reduces inflammation and release of bone degrading mediators, but did not affect phosphorylation of c-jun NH(2) -terminal protein kinase (JNK), ERK, and p38 MAP kinase. GLPG0259 (1-5 μM; 48 h) leads to the reduction and remodeling of actin filamentation in prostate cancer (PCa) cell lines, LNCaP and PC3.
In Vivo: GLPG0259 (2 mg/kg, 10 mg/kg; i.p.; twice weekly for 7 weeks) impairs tumor cells lung metastasis in SCID beige mice bearing prostate cancer (PCa) cell lines P3 cells (i.v.).